NASDAQ:ITOS
Delisted

Iteos Therapeutics Stock Signals

etoro logo Buy ITOS
*Your capital is at risk
$10.15
+0 (+0%)
At Close: Nov 28, 2025

Latest Data & Signals Issued

Below are some of the latest signals issued for Iteos Therapeutics Inc.

General

Signal Type Signal Value Data
Score 0.000 65 days ( 0 %
Last Price $10.15 0 %
Performance History
7 Days
$10.15 $10.15
0%
30 Days
$10.15 $10.15
0%
12 Mos
$8.54 $10.15
18.85%

9/18

Active Buy Signals

Specific Signals

Short Term
Net score: 60.14
Signal Type Signal Value Importance Data
High / Low N/A Very Low $10.15 - $10.15
Trend - 3 mos 0 % High Width: 0.0000000000002 %
Pred. range - 3 mos $10.15 - $10.15 Low 0 % - 0 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Nov 26, 2025 - 2 days
RSI Short Pivot Signal Buy Very Low Sep 10, 2025 - 57 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Buy Medium Oct 09, 2025 - 36 days
Short/Long MA 3 mos Buy Medium Oct 09, 2025 - 36 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 51.57
Signal Type Signal Value Importance Data
Trend - 12 mos 48.28 % Very High Width: 61.36 %
Pred. range - 12 mos $11.35 - $18.32 High 11.86 % - 80.50 %
Short MA 12 mos Buy Very High Sep 19, 2025 - 50 days
Long MA 12 mos Sell Very High Nov 18, 2025 - 8 days
Short/Long MA 12 mos Sell Very High Nov 18, 2025 - 8 days
Pivot Long Sell Low Jul 14, 2025 - 98 days
RSI Long Pivot Signal Buy Low Sep 19, 2025 - 50 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT ITEOS THERAPEUTICS INC.
Iteos Therapeutics
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used t...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
4.43% Jun 01
N
NVRI
$19.53
0.87% May 20
RUN
$12.83
15.51% May 06
GLBE
$31.61
4.05% May 05
SAP
$172.39
8.56% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE